Trial Profile
A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect Relationship Study of Hepalatide for Injection Combined With Pegylated Interferon in Subjects With HBeAg-positive Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Hepalatide (Primary) ; Peginterferon
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Shanghai HEP Pharmaceutical
- 03 Dec 2023 Status changed from recruiting to completed.
- 24 Jun 2023 Results (n=22) presented at the European Association for the Study of the Liver Congress 2023
- 11 Dec 2022 Planned End Date changed from 1 Jun 2023 to 1 Oct 2023.